Curis Lifesciences Limited to Acquire 51% Stake in Uninova Lifesciences
Curis Lifesciences Limited announced a strategic investment in Uninova Lifesciences Private Limited, acquiring 51% of its equity share capital. The transaction will be completed within 30 days, subject to fulfillment of conditions outlined in the Share Purchase Agreement. The Purchase Consideration for the acquisition is INR 20,65,500. Following the acquisition, Uninova Lifesciences Private Limited will become a subsidiary of Curis Lifesciences Limited.Uninova Lifesciences Private Limited was incorporated on October 22, 2021, and has an audited turnover of INR 5.39 crores for the Financial Year 2024-25. The company is engaged in the manufacturing and trading of pharmaceutical products.
The Board of Directors also appointed M/s NGST & Associates as the Internal Auditors for the Financial Year 2025-26, and M/s Sachin Thakkar and Associates, Company Secretaries, as the Secretarial Auditors for the Financial Year 2025-26.
Additional Details on Uninova Lifesciences Private Limited
| Particulars | Details |
|---|---|
| CIN | U24290GJ2021PTC126583 |
| Registered Office | C/121/A, First Floor, Sagar Estate-2, behind Sukhsagar Hotel, Sanand Cross Road, Sarkhej, Ahmedabad, Daskroi, Gujarat, India, 382210 |
| Authorised Share Capital | INR 30,00,000 |
| Paid-up Share Capital | INR 30,00,000 |
| Turnover for FY 2024-25 | INR 5.39 crores |
| Turnover for FY 2023-24 | INR 5.11 crores |
| Turnover for FY 2022-23 | INR 2.90 crores |
Internal and Secretarial Audit Appointments
| Particulars | Details |
|---|---|
| Internal Auditor Appointment Date | March 28, 2026 |
| Internal Auditor Term | Financial Year 2025-26 |
| Secretarial Auditor Appointment Date | March 28, 2026 |
| Secretarial Auditor Term | Financial Year 2025-26 |
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.